Mengyao Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mengyao Liu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ningyang Wang
Henan Key Laboratory of Brain Targeted Bio-nanomedicine, School of Life Sciences & School of Pharmacy, Henan University, Kaifeng 475004, China
1 shared publication - Qian Qing
Henan Key Laboratory of Brain Targeted Bio-nanomedicine, School of Life Sciences & School of Pharmacy, Henan University, Kaifeng 475004, China
1 shared publication - Qihang Su
National R & D Center for Edible Fungus Processing Technology, Henan University, Kaifeng 475004, China
1 shared publication - Wenya He
School of Pharmacy, Henan University, Kaifeng 475004, China
1 shared publication - Yan Zou
International Joint Centre for Biomedical Innovation, Henan Key Laboratory of Brain Targeted Bio-nanomedicine, School of Life Sciences, Henan University, Kaifeng, China
1 shared publication - Yang Liu
Translational Medicine Center, Huaihe Hospital of Henan University, Henan University, Kaifeng 475004, China
1 shared publication
Latest Publications
- Open Access
- 1 April 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (4) , 482
Engineering Nanomedicine for Non-Viral RNA-Based Gene Therapy of Glioblastoma
Glioblastoma multiforme (GBM) is the most common type of malignant tumor of the central nervous system, characterized by aggressiveness, genetic instability, heterogenesis, and unpredictable clinical behavior. Disappointing results from the current clinical therapeutic methods have fueled a search for new therapeutic targets and treatment modalities. GBM is characterized by various genetic alterations, and RNA-based gene therapy has raised particular attention in GBM therapy. Here, we review the recent advances in engineered non-viral nanocarriers for RNA drug delivery to treat GBM. Therapeutic strategies concerning the brain-targeted delivery of various RNA drugs involving siRNA, microRNA, mRNA, ASO, and short-length RNA and the therapeutical mechanisms of these drugs to tackle the challenges of chemo-/radiotherapy resistance, recurrence, and incurable stem cell-like tumor cells of GBM are herein outlined. We also highlight the progress, prospects, and remaining challenges of non-viral nanocarriers-mediated RNA-based gene therapy.
- 1 April 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (4) , 482
Open AccessEngineering Nanomedicine for Non-Viral RNA-Based Gene Therapy of Glioblastoma
Glioblastoma multiforme (GBM) is the most common type of malignant tumor of the central nervous system, characterized by aggressiveness, genetic instability, heterogenesis, and unpredictable clinical behavior. Disappointing results from the current clinical therapeutic methods have fueled a search for new therapeutic targets and treatment modalities. GBM is characterized by various genetic alterations, and RNA-based gene therapy has raised particular attention in GBM therapy. Here, we review the recent advances in engineered non-viral nanocarriers for RNA drug delivery to treat GBM. Therapeutic strategies concerning the brain-targeted delivery of various RNA drugs involving siRNA, microRNA, mRNA, ASO, and short-length RNA and the therapeutical mechanisms of these drugs to tackle the challenges of chemo-/radiotherapy resistance, recurrence, and incurable stem cell-like tumor cells of GBM are herein outlined. We also highlight the progress, prospects, and remaining challenges of non-viral nanocarriers-mediated RNA-based gene therapy.